RRJ Capital buys $50m Triplex Biosciences stake


Hong Kong and Singapore-based RRJ Capital is believed to have invested $50m in Chinese biotech company Triplex Biosciences.

The firm is understood to have picked up between 11 per cent and 19 per cent of the company according to a Deal Journal source.

Xiamen-based Triplex has a registered capital of $35.2m according to its website, which says it performs R&D, manufacture and sales for medical diagnostics reagents, instruments, diagnostics and health check services.

RRJ is currently planning one of the biggest-ever Asia-focused investment vehicles by targeting a $5bn fundraise less than a year after closing its maiden fund.

The firm is believed to have already received more than $3bn of commitments from investors and is expected to complete a first close in September.

Such a fundraise would dwarf the $2.3bn RRJ raised for its RRJ Capital Master Fund I in 2011, which closed $300m over target exactly 12 months ago.

Copyright © 2012 AltAssets